From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans

Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3u5xN89
via IFTTT

Read More

Cipla subsidiary clears USFDA inspection with zero observations

Cipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, Long Island, New York.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BoM65tl
via IFTTT

Read More

At 22, he built a gym machine in his garage. Now, the man behind the ‘Ferrari of fitness’ is looking to India

Technogym founder Nerio Alessandri is looking to expand the Italian fitness and wellness company's presence in India, where fitness facility membership remains below 1% of the population. Founded in 1983, Technogym has grown from a garage startup into a global brand serving athletes, gyms, luxury hotels and households.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH8bJRr
via IFTTT

Read More

Cancer drugs to get cheaper? Here’s what the latest government order says

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7MUrnm
via IFTTT

Read More

From Continuous Data to Trusted Health Intelligence: What Abu Dhabi and India Can Learn From Each Other About Predictive Health?

Predictive health will depend not on how much data health systems collect, but on whether they can validate it, govern it responsibly, and translate it into earlier action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xsof6CR
via IFTTT

Read More

Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in India

Sanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to prevent bleeding in haemophilia patients aged 12 years and older. Qfitlia offers unique protection for Haemophilia A and B patients, requiring only six injections annually. The approval follows promising results from the ATLAS phase 3 clinical trials. This advancement aims to enhance access to treatment options for patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE29pxY
via IFTTT

Read More

Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72My0Yt
via IFTTT

Read More